Hospital-acquired pneumonia (HAP), often caused by Pseudomonas aeruginosa, poses a significant health threat. Meropenem, a common therapeutic agent, faces emergent resistance during treatment. Using a rabbit HAP model, we assessed meropenem’s pharmacodynamics. Dose-response and emergent resistance displayed an inverted U relationship. Combining amikacin with meropenem suppressed resistance. Mechanisms included porin loss, efflux upregulation, and increased AmpC expression. Simulations identified meropenem 2 g i.v. q8h as an optimal regimen to suppress resistance. This innovative platform allows pre-clinical assessment, informing strategies to mitigate emergent resistance during HAP treatment with meropenem.
Related Posts
Why does Devil’s ivy in the Office make us more productive
Devil’s Ivy stands out as an excellent hanging plant, boasting large green leaves and trailing vines. Not only are they visually appealing, but they also excel at purifying the air by effectively removing toxins. While Devil’s Ivy is known for its low maintenance, occasional pruning is necessary to manage its growth.
Pulsed Field Ablation: A Safe and Effective Treatment for Women with AF
Atrial fibrillation (AF) is a heart rhythm that is irregular and typically very fast. Arrhythmia is the medical term for an irregular heartbeat. AF may result in blood clots in the heart. Additionally, the disease raises the risk of stroke, heart failure, and other heart-related issues. The top chambers of the heart, known as […]
Pioneering Double Lung Transplant from Living Donor Gives Indian Patient New Lease on Life
The first successful double lung transplant in India has been performed at Yashoda Hospitals, Secunderabad, saving a 23-year-old man from paraquat poisoning and pulmonary fibrosis. This is the fourth successful and rare double lung transplant case in the world and the first reported case of survival from this condition in India. The patient’s case was […]